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Abstract
GM crops have great potential to improve food quality, increase 
harvest yields and decrease dependency on certain chemical 
pesticides. Before entering the market their safety needs to be 
scrutinized. This includes a detailed analysis of allergenic risks, 
as the safety of allergic consumers has high priority. However, 
not all tests currently being applied to assessing allergenicity 
have a sound scientific basis. Recent events with transgenic 
crops reveal the fallacy of applying such tests to GM crops.
Genetically modified (GM) crops undergo rigorous safety assess-
ment before being allowed to enter the market. One aspect of GM 
foods that has drawn a lot of public attention is the assessment of 
their potential allergenicity. Protecting people with food allergies 
against accidental exposure to allergens has become an important 
focus for food manufacturers and regulators responsible for all food 
safety. A significant focus of the food industry is to keep food prod-
ucts that are not intended to contain a major allergen (e.g., peanut, 
milk, eggs or wheat) from being contaminated with one of the ma-
jor allergens. Likewise, the primary focus of the safety assessment 
for GM crops, as defined by the Codex Alimentarius Commission 
(Box 1)1, is to prevent the transfer of a gene encoding a major al-
lergenic protein (from any source), into a food crop that did not 
previously contain that protein.
The producers of GM crops and regulatory authorities focus on 
preventing avoidable increases in the risk of allergy in producing 
and accepting new GM crops. It should, however, be recognized 
that absolute avoidance of all risk is not achievable. Thus the as-
sessment that has been developed focuses on avoiding risks that are 
predictable and likely to cause common allergic reactions.
Before discussing the details regarding the approaches used for 
assessing potential allergenicity of GM crops and the drawbacks 
of some steps, it is important to put the risks associated with food 
allergy into perspective. The prevalence of food allergy is not well 
established but is estimated to be around 6% in young children 
and 3% in adults2.
Known potent allergenic foods like peanut or shrimp are not 
banned from the market, even though 1% of the population might 
develop allergic reactions upon exposure. In addition, market intro-
ductions in the recent past of novel foods like kiwi have resulted in 
the development of new allergies. Yet kiwi has not been removed 
from the market. Some of the major allergenic foods like fruits, 
nuts and fish are considered essential components of a healthy diet, 
and nobody would endeavor to deprive 99% of the population of 
these foods because 1% is at risk of developing food allergy. In-
stead, food labeling is used to help the allergic consumer avoid ex-
posure to foods that cause their reactions. Similar arguments could 
be made for new crops developed either by conventional breeding 
or by genetic modification to, for example, help combat malnutri-
tion in developing countries.
Furthermore, to date there is no documented proof that any ap-
proved, commercially grown GM crop has caused allergic reactions 
owing to a transgenically introduced allergenic protein, or that gen-
eration of a GM crop has caused a biologically significant increase 
in endogenous allergenicity of a crop3. However, the potential for 
the transfer of an allergen was illustrated in the 1996 case of trans-
genic soybeans into which the gene for a 2S albumin from the Bra-
zil nut had been transferred to enhance the methionine content of 
animal feed. Although the protein had not previously been recog-
nized as an allergen, a study sponsored by the developer of the crop, 
Pioneer Hi-Bred International ( Johnston, IA, USA) during prod-
uct development demonstrated IgE-binding with sera from Brazil 
nut–allergic subjects and positive skin prick tests to the transferred 
protein4. This protein is now known as the major allergen of the 
Brazil nut, Ber e 1. Despite being developed for animal feed only, 
the product was abandoned because of the obvious risk.
That experience provided guidance for development of the pre-
market allergenicity assessment process and demonstrated that spe-
cific, appropriate tests can prevent the transfer of a gene encoding 
a protein that might pose substantial risk. However, whereas abso-
lute protection against all potential allergic reactions to a newly in-
troduced protein can never be given, the allergenicity assessment of 
GM crops based on scientifically sound protocols should minimize 
the risks. It should be noted that some scientists and regulators have 
called for postmarket monitoring of GM crops to identify the de-
velopment of new allergies associated with the crop. The full Codex 
guidelines1, however, outlines the need for an effective premarket 
evaluation as the most effective tool to protect the public. There are 
technical, practical and economic issues that would need to be ad-
dressed in designing an effective postmarket monitoring system and 
are beyond the scope of this paper. Here, we focus on the scientific 
validity of protocols used in the premarket evaluation of the poten-
tial allergenicity of GM crops. In particular, we show how three tests 
that are commonly called for, and which have not been validated, can 
block development of potentially useful products.
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Evolution of guidelines for allergenicity 
assessment of GM crops
Guidelines for allergenicity assessment of GM crops were published 
in three sequential documents that have been broadly recognized. 
The first comprehensive document was published in 1996 by the 
International Food Biotechnology Council (IFBC, Washington, 
DC) in collaboration with the International Life Sciences Institute 
(ILSI, Washington, DC)5. This was followed in 2001 by the UN 
Food and Agriculture Organization (FAO)/World Health Orga-
nization (WHO) consultation recommendations6 and in 2003 by 
the Codex Alimentarius Commission guidelines1. The revised rec-
ommendations (FAO/WHO, 2001; Codex, 2003) were meant to 
correct shortcomings, although further clarifications are possible as 
we learn more about allergens and gain experience in test methods7. 
Several elements, however, are well established and have remained 
consistent throughout the three successive sets of recommendations.
All documents agree that introducing known allergens into a 
different species needs to be avoided as the primary risk is to those 
with existing allergies. If the source of the gene is a common aller-
genic food, or if the protein displays significant sequence identity 
with known allergens, the candidate protein should be evaluated 
for IgE binding using a sufficient number (e.g., for >95% confi-
dence) of sera from patients allergic to the source of the allergenic 
food or to the sequence of the matched allergen. Those tests should 
reveal whether the gene codes for a yet unidentified allergen from 
a common allergenic source or whether IgE against known aller-
gens cross-reacts with the homologous new transgenic protein. An-
other parameter included in all three guidelines is resistance of the 
candidate protein to digestion by pepsin, the rationale being that 
pepsin-resistant food proteins are more prone to induce systemic, 
severe symptoms. Perhaps more importantly, such stable proteins 
are also thought to be more potent sensitizers than proteins that 
are readily digested in the gut (that is, they are risk factors for in-
duction of new allergies).
The IFBC-ILSI and FAO/WHO guidelines both used a deci-
sion tree to evaluate the risk of allergenicity5, 6, as reviewed previ-
ously7. The IFBC-ILSI document recommended in vivo clinical 
testing (skin-prick tests (SPT) and double-blind placebo-controlled 
food challenges (DBPCFC)), even if in vitro assays had demon-
strated a lack of IgE binding for proteins from an allergenic source, 
if the protein sequence included as little as a single eight-amino-
acid match to a known allergen. Even so, the FAO/WHO recom-
mendations designated in vivo clinical testing as impractical and 
perhaps even unethical under most circumstances as a risk assess-
ment tool, and suggested instead that negative serum testing alone, 
or in some circumstances SPT testing, but not food challenges, 
might be necessary to demonstrate a lack of risk. Another change 
recommended by the FAO/WHO6 guideline was a six-amino-acid 
match to indicate a risk of cross-reactivity with allergens, rather 
than an eight-amino-acid match indicated by IFBC-ILSI5. Two 
additional new elements were added to the FAO/WHO (2001) rec-
ommendations: targeted serum screening—in which serum sam-
ples of patients allergic (or at least sensitized) to allergen sources 
broadly related to the source of the gene (sharing similar high taxo-
nomic groups; e.g., monocots, dicots or arthropods) are used to de-
tect or exclude potential cross-reactivity—and animal model test-
ing. Targeted serum screening was recommended even when the 
transgenic protein did not demonstrate significant sequence identity 
to a known allergen or when the specific serum screening—using 
sera from subjects allergic to the source or the sequence-matched 
allergen—was negative. Animal testing was included despite rec-
ognition that validated models predicting risk of sensitization in 
humans do not (yet) exist.
The Codex Alimentarius Commission guidelines abandoned 
the risk assessment based on a decision tree and adopted a weight-
of-evidence approach1. A decision tree was found to be too rigid 
in a situation where no single criterion is sufficiently predictive 
and evidence derived from several types of information, based on 
tests with different levels of validation, needs to be taken into ac-
count. Codex clearly emphasized the need to use scientifically val-
idated testing, specifically removing the demand for nonvalidated 
animal tests and targeted serum screens and calling for validation 
of short-sequence matching routines. Instead, a 35% identity over 
an 80-amino-acid window was recommended as a sufficiently con-
servative prediction for potential cross-reactivity. These recommen-
dations have not been accepted by some regulators. Clearly, the ex-
istence of multiple documents with diverging recommendations 
coming from different organizations has resulted in confusion and 
sometimes arbitrary inclusion of tests upon request from regula-
tory authorities. In some cases, regulators continued to base their 
judgment on nonvalidated (e.g., animal models) or even rejected 
(short-peptide matches) tests.
Box 1. Risk assessment of genetically modified crops
The Codex Alimentarius Commission, under the FAO and the WHO, adopted guidelines in 2003 to harmonize the premar-
ket risk assessment process for plants derived from biotechnology (GM plants) in the global market1. The guidelines were 
approved by the Codex Commission and are intended to guide countries in adopting consistent rules that provide a strong 
food safety evaluation process while avoiding trade barriers. Each new GM crop requires a premarket safety assessment 
to evaluate intended and unintended changes that might have adverse human health consequences caused by the trans-
fer of the DNA (genes). The goal is to identify hazards, and if found, to require risk assessment and where appropriate 
develop a risk management strategy (e.g., do not approve, approve with labeling and/or monitoring, or approve without 
restriction).
The process is based on the science and requires the use of methods and criteria that are demonstrated to be predic-
tive. New methods should be validated and demonstrated to enhance the safety assessment.
The framework to guide evaluation of potential safety issues requires detailed characteristics of:
• The GM plant and its use as food
• The source of the gene
• The inserted DNA and flanking DNA at the insertion site
• The expressed substances (e.g., proteins and any new metabolites that result from the new gene product)
• The potential toxicity and antinutritional properties of new proteins or metabolites
• The introduced protein compared with those known to cause celiac disease if the DNA is from wheat, barley, rye, oats or 
related grains
• The introduced protein for potential allergenicity
• Key endogenous nutrients and antinutrients including toxins and allergens for potential increases for specific host plants 
(DNA recipients)
Certain steps in the assessment require scientific assessment of existing information; others require experiments, in 
which case assay validation, sensitivity and auditable documentation are required.
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Assessment protocols
Here, we look at the scientific soundness of the principles and pro-
tocols for allergenicity assessment and present some recent case 
studies to illustrate the inappropriateness of nonvalidated meth-
ods for allergenicity assessment, whether part of the FAO/WHO5 
recommendations or the Codex6 guidelines. Figure 1 outlines the 
Codex guidance’s weight-of-evidence approach to evaluate the po-
tential risk of food allergy.
Gene source. The process begins with an evaluation of the source 
of the gene. If the source of the gene encoding the new protein is a 
commonly allergenic food (e.g., peanut, hazelnut, hen’s egg or cow’s 
milk), a respiratory allergen (e.g., birch or grass pollen or house dust 
mite) or a contact allergen (latex), IgE-binding studies using sera 
from patients allergic to the source are required to ensure that the 
protein encoded by the gene does not bind IgE from those allergic 
to the source. For serum selection, demographic factors need to be 
taken into account. Both age and habitat have been shown to in-
fluence the molecular recognition profiles of specific IgE (Box 2). 
The number of sera needed is dependent on the degree of confi-
dence considered necessary (largely a political and socioeconomic 
issue) and the prevalence of recognition of the hypothetical aller-
gen. In other words, do we accept a 5% chance of an allergic reac-
tion in 1% of the population allergic to the source or do we want 
to be more protective and only accept a 1% chance of a reaction in, 
for example, 0.01% of that population? Choosing to lower the risk 
requires a higher number of sera.
If the source of the gene rarely causes allergies, it would be dif-
ficult or impossible to find enough qualified serum donors to per-
form statistically valid tests. However, that also means the number 
of individuals in the population who would be at immediate risk 
of reactions if the protein were an allergen would be small. In such 
cases, the number of individuals is not as important as the specificity 
of the test and evidence of clinical relevance of the allergenic source.
Bioinformatics. The amino acid sequence of all transferred pro-
teins, regardless of the source, are to be compared with known aller-
gens by FASTA or BLAST algorithms to determine if any identity 
match is sufficiently high to suspect that the protein might cause 
allergic cross-reactions. This is not meant to be a stand-alone test, 
but rather to identify proteins that would require serum testing, 
using donors with specific allergies to the source of the sequence-
matched allergen to evaluate potential IgE binding. If the identity 
match is high (e.g., >70% over most of the length of the protein), 
Figure 1. Schematic interpretation 
of the weight-of-evidence approach 
described by the Codex Alimentarius 
Commission Guidelines for 
Allergenicity Assessment in 2003 
(ref. 1). In the figure, the four main 
areas of evidence are depicted with a 
graphic representation of the evidence 
representing maximum risk on the 
right (high side of the triangles). The 
weight of the evidence in each of the 
areas is influenced by the quality of 
the factors depicted in the yellow 
boxes. On the basis of the imperfect 
nature of the test methods available 
to distinguish between allergenic 
and nonallergenic proteins, scientific 
interpretation is necessary to reach 
a balanced and useful conclusion 
regarding the potential risks of 
allergy associated with each new food 
product.
Box 2. Spaniards are different from Dutchmen
Exposure to allergen is an essential prerequisite for sensitization47. An exception to this rule is cross-reactivity: for exam-
ple, exposure to birch pollen can induce allergy to apple, cherry and hazelnut27, 48, 49. This is typically seen in those areas of 
the world where birch pollen exposure is high, such as The Netherlands. In the absence of birch pollen, apple allergy also 
exists, for example, in Spain. In a recent European multicenter study, almost 400 people allergic to apple from four coun-
tries were compared to identify potential cross-reactive causes48. As expected Dutch, and others (Austrian and Northern 
Italian) individuals were allergic to apple because they were allergic to birch pollen. IgE binding the major birch pollen al-
lergen Bet v 1 cross-reacted with the homologous major apple allergen Mal d 1. Symptoms induced by Mal d 1 were almost 
exclusively mild and restricted to the oral mucosa. Spanish participants had not been exposed to birch pollen and were 
shown to be sensitized to a non-pollen–related allergen identified as a lipid transfer protein (Mal d 3). Although the major-
ity exclusively have mild symptoms in the oral cavity, it was demonstrated that IgE against lipid transfer protein is a signifi-
cant risk factor for the development of severe systemic symptoms, as were observed in 25% of the Spanish individuals48. 
This study clearly illustrates that the outcome of allergenicity assessment of GM crops using serum samples of patients with 
largely identical clinical symptoms upon consumption of apple is strongly influenced by the geographic origin of the pa-
tients. Spanish are simply different from Dutch apple-allergic patients due to differences in exposure or other local environ-
mental factors; variations in genetics of these populations cannot account for the marked differences. In the former case, 
assessment will focus on non-pollen–related apple allergens; in the latter, on birch pollen–related allergens. Similar pat-
terns have been reported for cherry allergy with Pru av 1, a homolog of Bet v 1, being the dominant allergen, compared 
with lipid transfer protein in cherry, peach and hazelnuts as the primary allergen in the Mediterranean areas27, 49. These 
studies highlight the need for good patient characterization and selection before the use of their sera in allergenicity assess-
ment protocols, as differences in the prevalence of IgE sensitivity is possible in the same foods, in different populations.
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the potential for cross-reactivity is high and the risk would proba-
bly be close to that posed by the matched allergen. Matches shar-
ing between 50% and 70% overall pose a moderate risk of cross-
reactivity and should be tested for IgE binding. If the match is 
<50% identical, the risk of cross-reactivity is expected to be low8. 
Even so, a conservative threshold value of 35% identity over any 
80-amino-acid segment of the transferred protein contained in both 
the FAO/WHO6 and Codex documents1 was intended to iden-
tify conserved gene segments representing functional motifs, which 
might retain conformational epitope structure as well. Proteins with 
higher matching identities (e.g., >35% identity) are recommended 
for testing of IgE binding.
On the basis of literature searches, only a few examples of en-
dogenous proteins from sources suspected of cross-reactivity dem-
onstrate significant IgE cross-reactivity for proteins sharing be-
tween 35% and 50% identity over the entire length of both proteins, 
and quantitative IgE binding and basophil histamine release (an ex 
vivo test of the circulating effector cells triggered to release hista-
mine by IgE cross-linking) demonstrate only partial reactivity7. The 
lack of known examples of cross-reactivity associated with proteins 
sharing only 35% identity over 80 amino acids suggests the crite-
rion is too conservative as it would overpredict potential cross-re-
activity. One alternative is to focus on overall sequence alignments, 
as suggested by Ladics et al.9. Another alternative would be to in-
crease the percent identity for the 80-amino-acid window closer to 
a level (possibly >50% identity) where there are examples of at least 
weak in vitro cross-reactivity using sera from individuals having al-
lergic symptoms to the sources of both proteins10.
The bioinformatics step is relatively straightforward and should 
markedly reduce the risk of transferring even a minimally cross-
reactive protein. However, some allergens that may be matched 
are rarely noted as causing allergies and it would be virtually im-
possible to identify appropriate serum donors for a well-powered 
study. In such cases, the risk of potential allergy to the population 
from that protein is likely to be extremely low and regulators may 
be willing to waive the requirement for IgE testing. Choosing the 
appropriate allergen database to search is vital for a reliable se-
quence comparison10. AllergenOnline (http://www.allergenonline.
com) is the only database that is currently fully peer-reviewed re-
garding evaluation of published evidence of allergenicity. Other 
databases are available and the alternative of searching the Na-
tional Center for Biotechnology Information (NCBI; Bethesda, 
MD, USA) nonredundant database, with key-word limits can 
provide more updated sequences, but lacks an accurate screening 
method for relevance10.
Although there are not yet any publications reporting valida-
tion of the approach using 35% homology over an 80-amino-acid 
window (or >50% overall homology) to predict likely cross-reac-
tivity, it is clear that it is an improvement over methods using se-
quence homology over 6 or 8 amino acids11. These short peptide 
matches have not been validated as predictive tools and should be 
rejected on the basis of extremely high numbers of false-positive 
hits11, 12, 13, 14. The eight-amino-acid match was originally selected 
without evidence of predictability based on the idea that it would 
represent both a theoretical B-cell epitope as well as a minimum 
size for a conserved T-cell epitope5. Stadler and Stadler13 reported 
that a 6-mer match resulted in more than two-thirds of all pro-
teins in Swiss-Prot being predicted to be allergens, and >40% of 
the human genome being predicted as such. Obviously, the use of 
short amino matching searches (6–8 mer) is not a useful approach 
for allergenicity assessment, but it has never been truly renounced. 
Consequently, a few regulatory authorities sometimes still require 
bioinformatics analyses based on 6-mer matches (Box 3).
Serum IgE binding. Serum IgE testing to evaluate proteins from 
an allergenic source, or proteins with sequence identity (e.g., >35% 
over an 80-amino-acid widow or >50% overall) to a known aller-
gen works very well if performed properly15. Appropriate positive 
and negative control proteins or extracts of the allergenic source 
material are required to demonstrate assay validity. The positive test 
sera must be from clearly diagnosed allergic subjects who react to 
the gene source or sequence-matched allergen and its source. Neg-
ative control sera would typically include donors with allergies to 
other unrelated proteins as well as nonallergic subjects. A few rel-
atively well-controlled studies have been used to evaluate GM crop 
safety4, 15, 16, although the relevance of donor selection has not al-
ways been clear15.
The design and interpretation of assays for specific IgE can be 
complex. Potential confounding factors include the molecular ap-
pearance of the protein (e.g., monomeric versus multimeric, proper 
folding or misfolding, presence or absence of disulfide bonds, pres-
ence or absence of N-linked glycans) and abundance of the protein 
in the source material (that is, sensitivity). The test material must 
be representative of the form available in the GM food source. The 
tests should be capable of detecting IgE binding to linear and con-
formational epitopes, sometimes requiring two separate assays (e.g., 
under reducing and native conditions). Demonstration of specific-
ity of binding requires replicate samples with sera exposed to ap-
propriate inhibitors.
Moreover, it must be recognized that there are no absolute 
thresholds of serum IgE binding that provide absolute measure-
ment of safety or risk. Positive IgE tests without clinical relevance 
Box 3. Short peptide match: a lot of work for nothing
Pioneer Hi-Bred International and Dow AgroSciences (Indianapolis, IN, USA) developed a GM maize product containing 
the gene encoding Cry1F, from Bacillus thuringiensis. The product was approved for sale in the United States and Canada 
following full regulatory studies, including assessment of the potential allergenicity of the protein based on Codex guide-
lines1. The protein produced from this gene is toxic to lepidopteran larval pests, such as the European corn borer, but not 
to mammals16. The gene is from an organism not known to cause allergies. The sequence is not significantly identical to 
any known allergen based on overall FASTA alignment. It is <35% identical to any 80-amino-acid segment of known al-
lergens, which is the primary alignment criterion recommended by Codex1. Because of regulatory requests from Tai-
wan, an additional bioinformatics comparison was performed to identify any six-amino-acid matches with allergens. There 
was a single six-amino-acid match to the house dust mite allergen Der p 7 (ref. 16). The protein does not have any other 
alignment similarity to Der p 7, yet regulators from Taiwan required human allergic serum IgE testing to evaluate poten-
tial cross-reactivity. The results of the serum IgE test demonstrated a lack of IgE binding to Cry1F using sera from allergic 
subjects who had clear IgE binding to Der p 7 (ref. 16). The results satisfied the regulators and the product was approved. 
However, the tests were expensive and there is always a chance of obtaining a weak-positive IgE binding result. Even the 
slightest amount of binding would likely have led to extensive in vivo testing, but would have been unlikely to demon-
strate a risk of an allergic response in consumers as at least two IgE binding sites and high affinity are required to effec-
tively cross-link mast cells and trigger an allergic response (as discussed in reference 11).
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are common in clinical practice (e.g., due to the presence of cross-
reactive IgE to plant N-glycans). To avoid potentially confound-
ing test results, developers may want to remove glycosylation sites 
before introducing the new gene unless the glycan is needed for 
functionality. Serum from individuals with strong carbohydrate-spe-
cific IgE antibodies should be avoided for GM assessment to en-
sure selection of appropriate donors who should have IgE directed 
against peptide epitopes rather than carbohydrate. Otherwise, car-
bohydrate-binding sera would lead to designating most glycopro-
teins as an allergenic risk, although it is widely accepted that the 
glycans are unlikely to cause clinical food allergy17, 18. In the event 
the transgenic protein is glycosylated, alternative testing may be 
required to evaluate glycan structure or if IgE binding is demon-
strated, the relevance should be tested by basophil histamine release 
or in vivo allergen testing. Diagnosing allergic disease requires a 
holistic evaluation of diet, symptoms, SPT and/or specific IgE and 
elimination diet or challenge test19. Likewise, interpretation of IgE 
binding to GM proteins requires judgment. Strong, specific bind-
ing to the protein using appropriate donors should be taken as ev-
idence of risk. However, low levels of binding that are not clearly 
specific and close in affinity to the suspected cross-reactive aller-
gen may not indicate significant risk. If results are equivocal, SPT 
or challenges might be necessary to demonstrate the relevance of 
low levels of apparent specific IgE binding.
Stability in pepsin and abundance. The ability of the new protein 
to withstand digestion by pepsin is evaluated as a potential risk fac-
tor of allergenicity20, 21. Several potent food allergens are known 
to be very stable in an in vitro pepsin digestion assay, whereas it is 
thought that most dietary proteins are readily digestible22. How-
ever, some proteins not known to cause significant food allergies 
are also stable23. And some proteins known to cause food allergy, 
especially those inducing only oral allergy syndrome—mild tin-
gling or itch in the mouth, without substantial edema—are rela-
tively labile24. Thus far, food allergens from this last category are 
mainly found among cross-reactive allergens, where primary sensi-
tization occurs by inhalation (e.g., pollen or latex). These are there-
fore usually not designated to be ‘true’ food allergens25. Such pro-
teins are likely to pose little risk to consumers if expressed at low 
abundance in crops.
Some very stable proteins such as thaumatin-like proteins from 
apple and grape rarely cause allergy or possibly only mild reac-
tions26, whereas others, like the lipid transfer proteins from a va-
riety of sources, are very stable and may frequently cause severe 
reactions26, 27. Some of these stable proteins are inducible patho-
genesis-related proteins and expression is variable in foods, which 
may complicate their recognition as allergens28. There is also ev-
idence that some important pepsin-labile allergens become more 
stable with minor shifts in pH (e.g., from pH 2.5 to 2.75 for cod-
fish parvalbumin)29. Although the increased stability at moderate 
stomach pH values may help explain the allergenicity of some of 
these proteins, the use of standard pepsin stability testing at pH 1.2 
or 2.0 still has a good demonstrated predictive value30.
An additional risk factor for food allergy is the abundance of 
the protein in food, as many major food allergens account for >1% 
of the protein in high-protein allergenic foods20. Others, such as 
lipid transfer proteins and parvalbumins are less abundant. Abun-
dant, pepsin-stable proteins are more likely to survive digestion in 
sufficient quantities to facilitate sensitization and become signifi-
cant food allergens. The typical quantity consumed of specific foods 
would be expected to have an impact as well, so nonabundant, sta-
ble proteins may be potent allergens if a large amount of food is 
consumed. However, additional scientific data would be required 
to establish completely objective criteria for acceptance or concern 
based on stability and abundance. Currently the results are judged 
relative to common, potent food allergens.
Box 4. Mission impossible: evaluation of changes in endogenous ‘hypo-allergenicity’
A transgenic herbicide-tolerant rice, Liberty Link-rice (LLRICE62), was produced by Aventis CropScience (now Bayer Crop-
Science, LP, Research Triangle Park, NC, USA), by inserting the gene for phosphinothricin-N-acetyltransferase (PAT) from 
a bacteria that has not been reported to be allergenic, nor does it share significant sequence identity with any known al-
lergens. The nonglycosylated PAT protein is rapidly digested by pepsin under standard conditions50. On the basis of these 
characteristics, there is no need to test IgE binding to evaluate the potential allergenicity of the PAT protein. US regulators 
approved the product in 1999 (http://www.agbios.com/dbase.php). However, because rice has been reported (rarely) to 
cause allergic reactions in humans, the developer performed an in vitro IgE binding study of LLRICE62 to compare endog-
enous allergenicity to a nontransgenic cultivar after their interpretation of the IFBC-ILSI recommendations and based on 
historical questions from regulatory agencies (pre-1999). Because true (challenge-positive) rice-allergic individuals cannot 
easily be found, sera of food-allergic subjects with rice-specific serum IgE or skin test–positive reactions to rice extract, 
or individuals with clinical histories suggestive of rice allergy were used. However, rice-food allergy was not confirmed 
by food challenge. These individuals were probably sensitized to grass pollen or inhaled rice flour and may be unaffected 
when ingesting rice based on a paucity of published cases of proven rice allergy and our experiences51, 52.
The unpublished study (personal communication, Donna Mitten, Bayer CropScience, data reviewed by R.E.G.) revealed 
no significant differences in IgE binding and allergen content between the GM and a genetically similar traditional rice vari-
ety. The value of a study based on sera of patients with unconfirmed rice allergy is questionable. Regardless, Canadian au-
thorities approved LLRICE62 in 2006 having been satisfied with the assessment of potential allergenicity that included an 
evaluation consistent with current guidelines in addition to the results of the serum study (http://www.hc-sc.gc.ca/fn-an/
gmf-agm/appro/nf-an90decdoc_e.html). It can be argued that it is not justified to evaluate GM crops for potential changes 
in endogenous allergenicity for a food with extremely low allergenicity because results will generally be meaningless.
However, the story does not end here. Recently, a small amount of seed from a similar GM event (LLRICE601) was 
discovered in a commercial ‘nontransgenic’ rice variety. In order to quickly respond to regulatory requests for informa-
tion about studies of LLRICE601 safety, Bayer CropScience considered the earlier Canadian request for LLRICE62 and de-
cided to perform a similar study if feasible. However, the original sera used for the previous study were no longer available 
(personal communication, Donna Mitten). Communications with clinical allergists (including M.E., D.H., H.A.S.) in Austra-
lia, Japan, Korea, Taiwan and the United States (by R.E.G) indicated the extreme difficulty in obtaining serum donors with 
clinically defined allergy to rice (as food), and the study was not performed. But, because people who are allergic to rice 
should avoid eating it, and so few are allergic, it is not clear that there would be any value in performing such a study.
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GM crop allergenicity assessment—what is not 
(yet) useful?
As the assessment of the allergenicity of GM crops has evolved, 
scientific evaluation of some tests and criteria included in earlier 
guidance has demonstrated that some specific approaches are not 
(yet) particularly useful (e.g., six- to eight-amino-acid matches, tar-
geted serum tests). Additionally, some new approaches have been 
espoused that are not sufficiently validated in terms of predicting al-
lergenicity for use in regulatory decision making, although in some 
cases continued research may be warranted.
Endogenous allergenicity. If a transgene is transferred to a com-
monly allergenic food, it appears logical to monitor the influence on 
endogenous allergenicity, which was recommended by the various 
guidelines on GM crop allergenicity assessment1, 5, 6. These docu-
ments, however, have not addressed the level of change that would 
be (un)acceptable. Several studies have been carried out compar-
ing endogenous allergenicity of nontransgenic and GM varieties. 
Monsanto (St. Louis, MO, USA) performed an evaluation of her-
bicide-tolerant soybeans using sera from soy-allergic subjects31, and 
also of a potential herbicide-tolerant GM wheat product using sera 
from ten subjects allergic to wheat. In a comparison of IgE bind-
ing, neither study demonstrated any significant differences between 
the GM crop and non-GM controls (R.E.G., poster presentation, 
World Allergy Organization meeting, Vancouver, BC, 2003). A 
study by Lehrer and Reese32, commissioned by Pioneer Hi-bred 
International, compared conventional and GM high–oleic acid soy-
beans using sera from five individuals selected for high IgE bind-
ing to soybean extract. A radioallergosorbent-inhibition (RAST-
inhibition) assay demonstrated similar IgE binding results between 
the GM and non-GM varieties. However, what is the risk and what 
should be done if statistically significant differences are detected?
Serum IgE binding and histamine release were tested in a com-
parison of ten varieties of Roundup Ready soybean (GM) developed 
by Monsanto and eight cultivars of non-GM soybean15. IgE-inhi-
bition tests demonstrated up to fourfold differences in IgE-binding 
potencies across both the GM and non-GM varieties, but overall 
the GM and non-GM varieties were not significantly different. That 
study illustrated that a head-to-head comparison of a pair of ran-
domly selected soybean varieties may lead to statistically significant 
differences, even though the apparent allergenicity of the individ-
ual varieties falls within the range of responses to several commer-
cially available non-GM soybeans. Apart from the fact that serum 
samples used in this study originated from subjects that were neg-
ative to soy by food challenge (or were not challenged), the vari-
able IgE binding results clearly highlight an aspect that should be 
taken into account when evaluating effects on endogenous allerge-
nicity: natural variation of allergenicity of available food crops due 
to differences in the genetics of commercial varieties, and interac-
tions with the environment (e.g., nutrient availability, differences 
in moisture, temperature, plant pathogens). It is unreasonable to be 
more stringent toward GM crops with respect to changes in en-
dogenous allergenicity than can already be accounted for by natu-
ral variability. Basing judgment on statistical significance alone has 
no clinical meaning if natural variability is larger. Importantly, the 
whole discussion about endogenous allergenicity has limited rele-
vance because patients allergic to the food will (should) avoid eat-
ing it anyway, GM or not, to avoid allergic reactions.
The soy study results15 suggest that there is wide variation in 
IgE binding to different varieties of the same species of non-GM 
crops, but few studies have been performed to study the question in 
a systematic way. Various groups have addressed differences in al-
lergenicity between non-GM apple cultivars, focusing on two ma-
jor apple allergens, the birch pollen–related allergen Mal d 1 and 
a lipid transfer protein, Mal d 3. Differences in allergenicity have 
been found by IgE-binding and IgE-inhibition studies, immuno-
assays for quantifying allergens, in vitro basophil histamine release 
and genomic sequence variability, but also by SPT and DBPCFC 
as illustrated below.
Sequence variability, possibly translating into differences in al-
lergenicity, has been recently reported for both Mal d 1 and Mal 
d 3 in different apple cultivars33. Most studies focusing on differ-
ences in allergenicity of apple cultivars have used IgE-based bind-
ing (in vitro and in vivo) as an endpoint. A recent study has evalu-
ated IgE binding and SPT reactivity as well as measuring Mal d 3 
content, comparing ten cultivars of apples34. The Mal d 3 content 
varied more than sixfold on a dry material basis across cultivars. The 
mean wheal area resulting from SPT of the highest Mal d 3 con-
Box 5. A controversial nonvalidated animal model
A gene encoding an α-amylase inhibitor 1 (αAI) was transferred from kidney bean to field peas to make peas resistant to a 
bruchid storage beetle53. Because of the recommendation for animal model tests by the FAO/WHO6, the developer tested 
the product in a mouse model using repetitive intragastric sensitization followed by intratracheal challenge54. This model 
had not previously been used to predict allergenicity of food proteins and we are aware of no other studies that have used 
an airway challenge or measure of pulmonary cellular infiltration to evaluate food allergenicity. The test results demon-
strated stronger eosinophil accumulation in the lungs in mice sensitized and challenged with the GM pea (or αAI from the 
pea), compared with the kidney bean54. This supports increased Th2 inflammation, but not necessarily IgE-mediated al-
lergy. The report described structural differences of the N-linked glycan on αAI expressed in peas compared to kidney 
bean. There was also evidence of different proteolytic processing of the C terminus of the protein. The authors concluded 
that differences in post-translational proteolytic processing were responsible for the apparent enhanced immunogenicity of 
the GM product53.
The mechanism leading to the altered response in mice is not clear, but more importantly, the model has not been 
widely tested with allergenic and nonallergenic proteins as would seem necessary based on Codex guidelines1. In the case 
of the GM AI pea, the differences found in glycan structure and protein processing would have been more appropriately 
investigated by human serum testing to evaluate IgE binding using serum donors with allergies to legumes if regulators 
wished to have testing beyond the bioinformatics, pepsin digestion and characterization of the protein.
Despite the fact that no scientific evidence was provided for an increased risk of IgE-mediated food allergy in humans, 
the study aroused a storm of negative publicity for GM crops, being an allergy risk55. Although the developer did not re-
port results of a bioinformatics evaluation of the protein, in our hands a FASTA search of AllergonOnline (http://www.Aal-
lergenoOnline.com/), version 7.0, revealed one match of 41% identity over an 80-amino-acid segment to peanut agglu-
tinin precursor, a putative allergen. The overall identity was 34.5%. Although this low level match is not likely to indicate 
cross-reactivity, it is above the Codex criterion. The data suggesting that peanut agglutinin is an allergen should be eval-
uated in making a final decision on whether to perform human serum-IgE testing, before any regulatory decision to ap-
prove the GM crop. In any event, data from a mouse model should not be relied upon to predict allergenicity.
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tent apple variety ( 55 mg/g) was significantly higher ( threefold) 
than the mean wheal area for the two varieties with lower concen-
tration ( 10 mg/g) of Mal d 3. One may infer from the SPT results 
and Mal d 3 quantities that the cultivar with the highest levels of 
the allergen (Starking) is probably three times more allergenic on 
a gram basis than those with lower levels (e.g., Golden Delicious). 
Similar studies35 were carried out with 88 apple cultivars focusing 
on both Mal d 1 and Mal d 3, although not all the results are pub-
lished (R.v.R., unpublished data). In both cases, differences in al-
lergen content differed up to 100-fold between the extremes, both 
in allergen quantification and IgE-inhibition assays. Some of these 
differences had been observed in SPT and DBPCFC testing, with 
about tenfold differences between individual cultivars. These de-
tailed studies demonstrate the wide range of natural variability of 
allergenicity in a common non-GM food.
Similar tests of soybean varieties by in vivo skin reactivity and 
in vitro IgE binding of ten soy cultivars found up to sixfold differ-
ences in IgE-binding potencies36. Apart from differences between 
cultivars, natural variability in allergenicity can also occur due to 
harvest timing and storage conditions37, 38. Even between individ-
ual apples from a single cultivar and harvest, up to tenfold differ-
ences in allergenicity have been reported39. Yet clinicians and food 
safety experts do not recommend avoiding certain apple or soybean 
varieties, nor is there evidence of significant differences in clinical 
reactivity for the allergic consumer.
Overall, these studies demonstrate the need to establish natural 
variability of allergenicity of non-GM crops before demanding eval-
uation of changes in endogenous allergenicity of GM crops. Never-
theless, some regulatory authorities have interpreted the guidelines 
so broadly that they demand evaluation of changes in endogenous 
allergenicity of foods for which it is virtually impossible to find 
sufficient truly allergic patients for a well-powered study (Box 4).
Of course, in cases where there are specific reasons to suspect 
a major impact on expression levels of endogenous allergens, spe-
cial attention has to be given to evaluating allergenicity. This can, 
for example, be the case when a transcriptional activator is in-
serted or the transgene is inserted in the coding region for an al-
lergen. Such events should however, not go unnoticed by the de-
veloper of a GM crop as detailed molecular characterization of 
the insert and the protein as well as protein function are required 
by Codex1 (Box 1).
Targeted serum screens. The FAO/WHO6 recommendation for 
broadly targeted serum screens specifically stated that if the source 
of the transferred gene was a monocotyledonous plant (class Liliop-
sida), serum should be taken from 50 individuals with allergies to di-
verse monocot sources (e.g., some allergic to grass pollen, maize, rice 
or dates) to identify potentially cross-reactive allergens. However, in 
the Codex guidelines, this was recognized as unlikely to be predic-
tive1. There are four or five structural protein families (prolamins, Bet 
v 1-relatives, cupins and profilins) with representative clinically cross-
reactive allergens from taxonomically diverse sources40. Although a 
few individuals react to material from sources as diverse as represen-
tatives of an order (e.g., Fabales) or even higher group, most clini-
cally important cross-reactions are elicited by material from within 
the taxonomic family (e.g., Fabaceae), tribe (e.g., Phaseoleae) or, more 
commonly, genus (e.g., Phaseolus)41. Differentiating between clinical 
cross-reactivity, cosensitization and irrelevant IgE binding (low af-
finity or binding to cross-reactive carbohydrate determinants) is of-
ten complicated as clinical reactivity is rarely measured, rather some 
level of skin prick sensitivity or direct in vitro IgE binding is used to 
define cross-reactivity and this is likely to overestimate clinical reac-
tivity10, 42, 43. Although validated specific serum tests with samples 
from clinically well-characterized subjects allergic to the source of the 
gene—or allergic to a sequence-matched allergen—should be useful 
when the need is indicated, targeted testing is unlikely to provide re-
liable data for the assessment.
Animal models. The FAO/WHO6 recommendations called for 
evaluating each new GM crop with studies in two separate spe-
cies of animals and/or using two routes of sensitization in one 
species, even though the panel recognized that no current animal 
model is predictive of allergenicity in humans. There are still no val-
idated animal models for predicting allergenicity to food proteins, 
even though many models have been successfully applied to dis-
sect mechanisms of allergic responses and potential changes due 
to modification of the allergenic proteins44, 45. Even though many 
authors recognize that different animal models respond to specific 
proteins differently46, they still suggest using animal models in the 
safety evaluation process for GM crops. On the basis of the paucity 
of correlative data between any one animal model and human food 
allergenicity, and the complex genetic diversity that predisposes sub-
jects to allergy, it is not clear that any animal model could be useful 
in predicting the potential allergenicity in humans of a novel pro-
tein or GM crop. It is also not clear how one might combine re-
sults from two animal model tests to produce a predictive result. An 
unpublished study coordinated by the ILSI-Health and Environ-
mental Sciences Institute (Washington, DC) reported results from 
a multi-laboratory test of the most commonly used mouse strains 
(BALB/c, C3H/HeJ, A/J and BDF-1) using commonly recom-
mended protocols to evaluate IgE and allergic responses to iden-
tical samples of common potent allergens of peanut (Ara h 1 and 
Ara h 2) and milk (beta-lactoglobulin) compared with relatively 
nonallergenic proteins of spinach (RUBISCO) and soybean (li-
poxygenase). The responses to the potent allergens were equivalent 
or weaker than responses to the weakly or nonallergenic proteins 
(Thomas, K. et al., 2005 annual meeting poster, American Acad-
emy of Allergy Asthma and Clinical Immunology).
Box 6. Box 6 Balb/c mice no substitute for human IgE recognition evaluation
A gene encoding amarantin was transferred from Amaranthus hypochondriacus into maize56. Although the protein was di-
gested in the pepsin assay, comparing the sequence to known allergens identified a number of 6-, 7- and 8-amino-acid 
matches to known allergens56. Although noting overall homology to some allergenic proteins, the developer decided to 
use animal models to evaluate the allergenicity of the GM maize56. Comparing the amarantin sequence by FASTA demon-
strated up to 70% identity over an 80-amino-acid segment to known allergens and >40% identity for overall alignments 
to a number of important 11S globulin allergens7. Clearly, this should have set off an alarm calling for serum IgE testing, 
if not immediately convincing the developer that the protein was too risky to transfer. Instead, the immunogenicity of the 
product was tested in BALB/c mice, with results demonstrating no significant response and the authors suggested there 
was no significant risk of allergy56. Although it is not clear if this potential product has been submitted for regulatory re-
view anywhere, the Codex guidelines (2003) indicate that the amarantin-containing maize would require serum IgE test-
ing with sera from at least a number of buckwheat- and/or Brazil nut–allergic subjects and possibly others.
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On the basis of current knowledge, therefore, we recommend 
continuing research to evaluate potentially predictive animal models 
but caution against testing potential products at this time as there 
is no scientific validation demonstrating predictive values that are 
acceptable for risk evaluation. This opinion is also reflected in the 
recommendations of the Codex Alimentarius Commission1. Pro-
ducers as well as regulators are sometimes confused about which 
recommendations to follow. This is illustrated by two cases in which 
developers of GM crops used animal models to evaluate potential 
allergenicity. In one, case results were interpreted as demonstrating 
likely allergenicity of the GM crop (Box 5) and in another case to 
suggest absence of allergenicity, even though there is a strong po-
tential for cross-reactivity based on bioinformatics (Box 6). In ei-
ther case, there is no scientific justification for these conclusions.
Conclusions
The current safety assessment outlined in the Codex guidelines 
(2003)1 is based on the current state of knowledge regarding food 
allergens and risk, and is therefore well-suited to evaluate the po-
tential for increased risk in allergenicity of GM crops compared 
with the risk of allergy from the conventionally bred crop variet-
ies. The weight-of-evidence approach was adopted in part as it was 
recognized that there are exceptions to each component in the pro-
cess. Thus, each product must be reviewed on a case-by-case basis 
and experienced scientists must be able to interpret results in ag-
gregate. Key elements of this weight-of-evidence assessment are 
illustrated in Figure 1:
• Source of the gene: common allergen or not?
• Bioinformatics: sequence searches for matches of >35% identity 
over 80 amino acids (or of >50% overall identity for more re-
alistic risks).
• IgE-testing: does the introduced protein bind IgE-antibodies?
• Stability testing: is the expressed protein highly resistant to di-
gestion by pepsin?
• Abundance: is the protein abundant in the food (and stable)?
The premarket assessment recommended by Codex provides a 
mechanism to intercept GM crops that are likely to increase 
the risk of food allergy, as demonstrated by the identification 
of the Brazil nut 2S albumin transferred to maize, and the 
amarantin transferred to maize (Box 6) as proteins that would 
likely present significant health risks for specific populations 
of allergic consumers. The premarket screening process helps 
to avoid possible severe reactions in unsuspecting allergic con-
sumers and also prevents subsequent costly food and seed re-
calls that would be needed to prevent additional reactions.
There is no scientific justification for inclusion of the follow-
ing tests in allergenicity assessment because their predictive val-
ues have not been validated:
• Bioinformatics: short-peptide matches resulting in random 
false-positive hits.
• Animal models: useful for mechanistic studies but not applica-
ble for prediction of human sensitization to food.
• Endogenous allergenicity: natural variability needs to be taken 
into account first.
• Targeted serum screens: potentially high rate of false-positive 
and low probability of true-positive results.
Demanding inclusion of such nonvalidated tests can lead to 
the rejection of safe and beneficial products, excessive costs and, 
potentially, disruption of trade without any further reduction of 
risk. Importantly, the use of inappropriate tests such as unvali-
dated animal models in place of more appropriate tests could lead 
to the introduction of a product that does pose substantial risk 
for a group of allergic consumers.
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